Related Experiment Videos
Pain management in sickle cell disease
E Jacob1,
1Hematology/Oncology Unit, Children's Hospital Oakland, CA, USA. ejacob@samuelmerritt.edu
Summary
Sickle cell disease pain management is challenging, often leading to undertreatment. Guidelines recommend adequate opioid analgesics, addressing patient concerns and fears of addiction.
Area of Science:
- Pain Management
- Hematology
Background:
- Sickle cell disease (SCD) presents unpredictable, severe pain, challenging effective management.
- Variability in pain management stems from differing views on opioid suitability, administration routes, and addiction risks.
- Inadequate pain management in SCD is common, leading to undertreatment of acute and chronic pain.
Framework:
- The American Pain Society (APS) developed evidence-based Clinical Practice Guidelines to improve SCD pain management.
- Guidelines address pharmacologic strategies, challenges, and concerns regarding opioid use and addiction in SCD patients.
Implementation:
- Clinicians should assess patients' knowledge of medications and past effective doses.
- Requests for specific analgesics or dosages should be viewed as informed preferences, not drug-seeking behavior.
- Effective communication and accurate assessments are crucial for providing adequate opioid analgesics.
Implications:
- Improved understanding of patient concerns regarding analgesic side effects can enhance trust.
- Adherence to APS guidelines can mitigate undertreatment and inappropriate management of SCD pain.
- Addressing fears of addiction while ensuring adequate pain relief is essential for patient well-being.